Take Homes in CAR T-cell Therapy

Take Homes in CAR T-cell Therapy

Source:

Jaeger, U et al. Abstract 1194. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
December 09, 2020
1 min watch
Save

VIDEO: Myc expression may predict remission response in diffuse large B-cell lymphoma

Source:

Jaeger, U et al. Abstract 1194. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition.

“Patients who had a high Myc expression by immunohistochemistry had worse outcomes. This is interesting because in the pivotal CAR T-cell therapy trials for diffuse large B-cell lymphoma, we haven't seen that double hit lymphoma or double expressor lymphoma has really been a predictor for worse outcomes. Here, they quite simply looked by immunohistochemistry for Myc expression,” Locke told Healio in a video interview.